Bart Klein - ProQR Therapeutics VP Property
| PRQR Stock | USD 3.38 0.07 2.11% |
Insider
Bart Klein is VP Property of ProQR Therapeutics BV
| Address | Zernikedreef 9, Leiden, Netherlands, 2333 CK |
| Phone | 31 88 166 7000 |
| Web | https://www.proqr.com |
ProQR Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1486) % which means that it has lost $0.1486 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6714) %, meaning that it created substantial loss on money invested by shareholders. ProQR Therapeutics' management efficiency ratios could be used to measure how well ProQR Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 12/11/2024, Return On Tangible Assets is likely to drop to -0.21. In addition to that, Return On Capital Employed is likely to drop to -0.32. At this time, ProQR Therapeutics' Non Current Assets Total are relatively stable compared to the past year. As of 12/11/2024, Other Current Assets is likely to grow to about 1.2 M, while Total Current Assets are likely to drop slightly above 100.7 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Howard Lovy | Arrowhead Pharmaceuticals | N/A | |
| Mark Davis | Arrowhead Pharmaceuticals | N/A | |
| Michael BA | Alnylam Pharmaceuticals | 66 | |
| Bronson Crouch | Instil Bio | 51 | |
| FMEDSCI MD | Achilles Therapeutics PLC | 49 | |
| Robert Bazemore | Nuvation Bio | 53 | |
| David Hanley | Nuvation Bio | 54 | |
| Weidong Zhong | Terns Pharmaceuticals | 58 | |
| CPA CPA | NextCure | 61 | |
| Kathryn Falberg | Nuvation Bio | 60 | |
| James Brady | Spero Therapeutics | N/A | |
| Ted Yednock | Annexon | 66 | |
| Larry Mattheakis | Annexon | 67 | |
| MBA BS | CytomX Therapeutics | 45 | |
| DPHIL DPhil | CytomX Therapeutics | 57 | |
| Adam Zlotnick | Assembly Biosciences | N/A | |
| Michelle Doig | Nuvation Bio | 46 | |
| Angela MD | Spero Therapeutics | N/A | |
| Alfred Boyle | Alnylam Pharmaceuticals | N/A | |
| Karl MD | Achilles Therapeutics PLC | 57 | |
| Robert Coutts | Achilles Therapeutics PLC | 40 | |
Management Performance
| Return On Equity | -0.67 | ||||
| Return On Asset | -0.15 |
ProQR Therapeutics Leadership Team
Elected by the shareholders, the ProQR Therapeutics' board of directors comprises two types of representatives: ProQR Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ProQR. The board's role is to monitor ProQR Therapeutics' management team and ensure that shareholders' interests are well served. ProQR Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ProQR Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Aniz MD, Chief Officer | ||
| Daniel Boer, CEO and Member of Management Board | ||
| Domenico Valerio, Founder Board | ||
| Sarah Kiely, Vice Communications | ||
| Rene Beukema, Chief Corporate Devel. Officer, General Counsel, Corporate Secretary and Member of Management Board | ||
| Sheila Sponselee, VP Operations | ||
| Gerard Platenburg, Chief Innovation Officer | ||
| Sandra Kolk, Financial Controller | ||
| Bart Klein, VP Property | ||
| Jurriaan Dekkers, Chief Officer |
ProQR Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ProQR Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.67 | ||||
| Return On Asset | -0.15 | ||||
| Profit Margin | (1.30) % | ||||
| Operating Margin | (2.19) % | ||||
| Current Valuation | 300.81 M | ||||
| Shares Outstanding | 105.91 M | ||||
| Shares Owned By Insiders | 14.49 % | ||||
| Shares Owned By Institutions | 24.95 % | ||||
| Number Of Shares Shorted | 413.76 K | ||||
| Price To Earning | (1.97) X |
Pair Trading with ProQR Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ProQR Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ProQR Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against ProQR Stock
| 0.83 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.65 | PFE | Pfizer Inc Fiscal Year End 4th of February 2025 | PairCorr |
| 0.64 | LLY | Eli Lilly | PairCorr |
| 0.59 | VALN | Valneva SE ADR | PairCorr |
| 0.56 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
The ability to find closely correlated positions to ProQR Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ProQR Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ProQR Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ProQR Therapeutics BV to buy it.
The correlation of ProQR Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ProQR Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ProQR Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ProQR Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for ProQR Stock Analysis
When running ProQR Therapeutics' price analysis, check to measure ProQR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ProQR Therapeutics is operating at the current time. Most of ProQR Therapeutics' value examination focuses on studying past and present price action to predict the probability of ProQR Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ProQR Therapeutics' price. Additionally, you may evaluate how the addition of ProQR Therapeutics to your portfolios can decrease your overall portfolio volatility.